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ABSTRACT
Background and Objectives: As shown in previous studies, pentraxin 3 (PTX3) can be a useful inflammatory marker for 
metabolic syndrome and central obesity. Serum PTX3 levels are also an independent factor associated with visceral fat area. 
The aim of this study was to assess the role of PTX3 as an inflammatory maker in patients with central obesity undergoing pri-
mary percutaneous coronary intervention (PCI) following an ST-segment elevation myocardial infarction (STEMI). Sub-
jects and Methods: From December 2007 to June 2008, 40 subjects (mean age: 61±11 years, M : F=34 : 6) with STEMI who 
underwent primary PCI were enrolled. We determined waist circumference, waist/hip ratio, body mass index (BMI), and 
visceral and total fat area via fat computed tomography (FAT-CT), and compared them with serum PTX3 concentrations. 
Results: The serum PTX3 concentration was closely related to FAT-CT-estimated visceral fat area (r=0.41, p<0.01) and to-
tal fat area (r=0.38, p=0.01), respectively. The serum PTX3 concentration was not related to waist circumference (r=0.27, p= 
0.20), waist circumference/hip ratio (r=0.25, p=0.16), BMI (r=0.04, p=0.80) and lipid profiles, respectively. Among the parame-
ters determining metabolic syndrome, an increasing visceral fat area had the strongest association with PTX3 concentrations. 
Conclusion: In patients with STEMI, PTX3 is associated with central obesity and it is significantly and independently corre-
lated with visceral fat area. FAT-CT-estimated visceral fat area is the most reliable factor associated with serum PTX3 levels 
in patients with STEMI and central obesity. (Korean Circ J 2010;40:308-313)
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Introduction
Arteriosclerosis has been shown to progress because of a 
persistent inflammatory reaction. Numerous studies have been 
conducted on the relationship between coronary artery dis-
eases and the inflammatory reaction,
1) with recent studies re-
porting that the inflammatory reaction is mutually associat-
ed with lipid metabolism and the metabolic syndrome.
2-4) Mar-
kers of inflammatory reaction are also markers in the diag-
nosis and prognosis of cardiovascular diseases, and in parti-
cular have had practical applications in the diagnosis and prog-
nosis of myocardial infarction, unstable angina, and heart fail-
ure. C-reactive protein (CRP), serum amyloid P, and pentraxin 
3 (PTX3) are among well known inflammatory markers.
5)6) 
CRP and PTX3 belong to the same PTX superfamily. Where-
as CRP is a short PTX and is synthesized in the liver upon sti-
mulation with primarily interleukin (IL)-6, PTX3 is a long PTX 
and is synthesized upon stimulation with diverse cytokines, 
such as IL-1 and tumor necrosis factor (TNF)-α, and it is spe-
cifically present in abundance in cardiac muscle.
7-9) Because of 
the latter characteristic, PTX3 is reported to be a more specific 
marker than CRP in cardiovascular diseases, and studies have 
been conducted on its usefulness as a marker for early diagno-
sis and prognosis in acute myocardial infarction patients and as 
an inflammatory marker in chronic heart failure patients.
10)11) 
Previous studies have reported that PTX3 is useful as an in-
flammatory marker in metabolic syndrome patients, and that Byung-Ju Shim, et al.   309
there is a correlation between PTX3 levels and abdominal 
obesity.
12) A recent study found that in terms of type of ab-
dominal obesity, PTX3 is closely associated with visceral fat 
tissues and it may also be associated with arteriosclerosis.
13) 
However, studies on the correlation of PTX3 levels with meta-
bolic syndrome or abdominal obesity in cardiovascular dis-
ease patients remain limited. Therefore, our study assessed 
whether there are associations among the concentration of se-
rum PTX3, the metabolic syndrome, and abdominal obesity 
in myocardial infarction patients undergoing primary per-
cutaneous coronary intervention (PCI) for ST-segment ele-
vation myocardial infarction. 
Subjects and Methods
Study participants
The study was conducted on 40 patients who had acute myo-
cardial infarctions and were hospitalized via the emergency 
room at Uijeongbu Saint Mary’s Hospital from December 
2007 to June 2008 and treated with primary PCI. In all pa-
tients, the serum PTX3 level was measured during the pro-
cedure and after admission; blood tests, echocardiography, 
physical measurements, and fat computed tomography (FAT-
CT) were also performed. Acute myocardial infarction was 
defined as ST segment changes corresponding to ischemia ac-
cording to American College of Cardiology/American Heart 
Association (ACC/AHA) guidelines, and acute symptoms of 
myocardial ischemia or the elevation of myocardial enzyme 
levels. Cases with liver cirrhosis, chronic renal failure (plasma 
creatinine >2.0 mg/dL), autoimmune diseases, or acute inflam-
matory diseases were excluded. Metabolic syndrome was defin-
ed according to the standard suggested by the National Cho-
lesterol Education Program, and the waist circumference was 
considered according to the recommended standard for the 
Asia-Pacific region; individuals with more than three of the fol-
lowing criteria were considered as having the metabolic syn-
drome: 1) waist circumference (male ≥90 cm, female ≥85 cm), 
2) triglyceride level (≥150 mg/dL), 3) high density lipoprotein-
cholesterol (HDL-C) level (male <40 mg/dL, female <50 mg/dL), 
4) blood pressure (≥130/85 mmHg), and 5) fasting blood glu-
cose level (≥100 mg/dL). Abdominal obesity was defined as 
visceral fat >103.8 cm
2.
14)
Hemotological analysis
For patients diagnosed with acute myocardial infarction, cor-
onary artery intervention was performed within 2 hours af-
ter arriving at the hospital and 10 mL of blood was collected 
from the femoral artery into ethylenediaminetetraacetic acid 
(EDTA) tubes, separated by centrifugation, and plasma was st-
ored at -70℃. For the measurement of PTX3 levels, enzyme 
linked immuno sorbent assay (ELISA) plates were coated with 
PTX3 capture antibody (Alexis Biochemicals, ALX-804-
464) at 4℃ overnight, blocked with 5% skim milk, and in-
cubated with EDTA-plasma samples and the standard PTX3 
protein at 37℃ for 2 hours. The samples and the standard pro-
tein were removed, washed, incubated with PTX3 detection 
antibody (Alexis Biochemicals, ALX-210-365B) at 37℃ for 
1 hour and incubated with streptavidin-HRP (Zymed, 43-
4323) at room temperature for 1 hour. The samples were incu-
bated with TMB (tetramethyl benzidine; chromogenic method) 
(R&D, DY999) at room temperature for 20 minutes; after 
staining, 2N H2SO4 was added to stop the staining reaction and 
the plates were read. In addition, basic biochemical tests were 
performed.
Physical measurements
Height and weight were measured by standardized devices 
and body mass index (BMI=kg/m
2) was calculated. The waist 
circumference was measured in the middle of the bottom of 
lower rib and the pelvic iliac crest. The hip circumference was 
measured from the widest circumference of the greater tro-
chanter area, and from this, the waist to hip ratio was calcu-
lated. Abdominal obesity was measured by FAT-CT (Soma-
tom Plus, Siemens, Germany), and the visceral fat area, the 
subcutaneous fat area, and the total fat area were measured. 
The visceral-subcutaneous fat ratio was calculated by divid-
ing the visceral fat area by the subcutaneous fat area. 
FAT-CT scanned the 4th and 5th radius area within a 10 mm 
range. Dyes were not used. Areas with Hounsfield Units from 
-150 to -50 on CT were considered as fat, and the total fat, 
visceral fat and subcutaneous fat areas were automatically 
calculated.
Statistical analysis
Statistical data analysis was performed using the Statistical 
Package for the Social Sciences (SPSS) version 16.0 (SPSS Inc., 
Chicago, IL, USA), and statistical values are presented as a 
mean±standard error. Serum PTX3 concentration and con-
tinuous variables between the non-obese group and the obese 
group were compared using independent sample t-test, and 
the correlation of the continuous variables of serum PTX3 
concentration and abdominal obesity was analyzed with the 
Pearson coefficient. Cases with a p less than 0.05 were consid-
ered to be statistically significantly different. 
Results
Clinical characteristics of patients
The study included 40 patients with a mean age of 61±11 
years, 34 (85%) of whom were men. In terms of associated dis-
eases, 15 (37.5%) of patients had hypertension, 11 (27.5%) had 
diabetes, 9 (22.5%) had hyperlipidemia, 17 (42.5%) met crite-
ria for metabolic syndrome, 24 (60%) had abdominal obesity, 
and 28 (70 %) were smokers (Table 1). 310   Pentraxin 3 and Central Obesity in STEMI
Among these patients, 4 (10%) were on statins; nonethe-
less, the use of statins did not appear to affect levels of PTX3 
(2.35±1.89 vs. 2.32±2.45, p=0.98), CRP (1.85±1.77 vs. 1.09± 
1.22, p<0.13) or serum lipids and it was not associated with 
abdominal obesity. 
The relationship between serum pentraxin 3 level 
and cardiovascular risk factors
Among the 40 patients, serum PTX3 concentration corre-
lated with the presence or absence of hypertension, diabetes, 
smoking, metabolic syndrome, or hyperlipidemia. When 
PTX3 levels were compared between those with or without 
each factor associated with the metabolic syndrome, there 
was no correlation with the waist circumference in male or 
female patients (male: r=0.19, p=0.29, female: r=0.48, p= 
0.34), BMI (r=0.04, p=0.80), triglycerides (r=0.07, p=0.96) 
HDL-C (r=0.15, p=0.35), blood pressure (SBP: r=0.81, p= 
0.62, DBP: r=0.15, p=0.37), or fasting blood glucose level (r= 
0.11, p=0.47). In addition, there was no correlation between 
PTX3 and CRP levels (r=0.24, p=0.14) (Table 2).
The relationship between serum pentraxin 3 con-
centration and abdominal obesity measured by fat 
computed tomography
Abdominal obesity was defined by the visceral fat area 
measured by FAT-CT (>103.8 cm
2), and serum PTX3 level 
and cardiovascular risk factors were compared according to 
the presence or absence of abdominal obesity. 
Serum PTX3 concentrations tended to be increased in pa-
tients with a large visceral fat area (r=0.41, p<0.01) and total fat 
area (r=0.39, p=0.01); however, a correlation to subcutaneous 
fat area (r=0.25, p=0.12) was not detected (Fig. 1). 
According to the presence or absence of abdominal obesity, 
in abdominal obesity patients, serum PTX3 concentration 
was significantly increased (3.00±2.61 vs. 1.33±0.81, p<0.01) 
(Fig. 2). Nevertheless, a difference of serum PTX3 concentra-
tion according to the presence or absence of metabolic syn-
drome was not seen (3.01±2.88 vs. 1.83±1.47, p=0.10). 
When the CRP level (1.38±1.47 vs. 1.33±1.51, p=0.91), 
which is known to be associated with abdominal obesity and 
cholesterol values, was compared according to the presence or 
absence of abdominal obesity, there was no significant differ-
ence (Table 3). 
Therefore, PTX3 levels measured in acute myocardial in-
Table 1. Baseline characteristics
n=40 (%)
Age (year) 61±11
Male 34 (85.0)
Hypertension 15 (37.5)
Diabetes mellitus 11 (27.5)
Smoking 28 (70.0)
CVA history 1 (2.5)
Metabloic syndrome 17 (42.5)
Dyslipidemia 09 (22.5)
Statin medication 4 (10)
Central obesity 24 (60)0
Culprit lesion
LAD 23 (57.5)
LCx 4 (10)
RCA 13 (32.5)
LVEF 53.2±11.7  
PTX3 (ng/mL) 2.33±2.23  
CVA: cerebrovascular accident, LAD: left anterior descending coro-
nary artery, LCx: left circumflex coronary artery, RCA: right coronary 
artery, LVEF: left ventricular ejection fraction, PTX3: pentraxin 3
Table 2. The relationship between cardiovascular risk factors and 
PTX3
n=40 Mean±SD Correlation p
Systolic blood pressure (mmHg) .0126±25 0.81 0.62
Distolic blood pressure (mmHg) .0073±12 0.15 0.37
Height (cm) 163.6±8.6 0.12 0.44
Weight (kg) 063.3±10.6 0.03 0.82
Body mass index (kg/m
2) 023.6±2.6 0.04 0.80
Waist circumference (cm)
Male 090.5±5.5 0.19 0.29
Female 097.0±7.0 0.48 0.34
Waist to hip ratio
Male .0.91±0.04 0.24 0.20
Female .0.93±0.03 0.03 0.95
Fasting blood sugar (mg/dL) .0149±77 0.11 0.47
Creatinine (mg/dL) 001.0±0.4 0.11 0.48
Lipid profile (mg/dL)
Total cholesterol  .0166±38 0.07 0.68
Triglyceride .0109±71 0.07 0.96
HDL-C .0039±8 0.15 0.35
LDL-C .0103±31 0.05 0.76
Biomarkers
hs-CRP (mg/dL) 01.36±1.46 0.24 0.14
Pro-BNP (pg/mL)  .0755±1966 0.14 0.52
CK-MB (ng/mL) 018.8±31.8 0.45 0.78
Troponin-T (ng/mL) 00.33±0.73 0.10 0.56
FAT computed tomography
Total fat area (cm
2) 203.0±70.8 0.39 0.01
Visceral fat area (cm
2) 106.9±40.7 0.41 <0.01
Subcutaneous fat area (cm
2) 098.0±38.8 0.25 0.12
Visceral/Total area ratio 00.52±0.09 0.16 0.32
PTX3: pentraxin 3, SD: standard deviation, HDL-C: high density li-
poprotein-cholesterol, LDL-C: low density lipoprotein-cholesterol, 
hs-CRP: high sensitivity C-reactive protein, BNP: B type natriuretic 
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farction patients correlated significantly to abdominal obesity 
measured by FAT-CT. 
Discussion
Our study suggests that among inflammatory markers wh-
ose levels are elevated in acute myocardial infarction patients, 
serum PTX3 is associated with metabolic syndrome and ab-
dominal obesity. 
Numerous studies have been conducted on the significance 
Fig. 1. The relationship between serum pentraxine 3 concentration 
and fat area of 3 groups. A: total. B: visceral. C: subcutaneous.
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Fig. 2. The difference on serum pentraxine 3 concentration accord-
ing to existence of central obesity.
Table 3. The difference between metabloic markers and serum 
PTX3 concentration according to existence of central obesity 
n=40
Central obesity
(Mean±SD) p
Presence Absence
Systolic blood pressure 
  (mmHg)
.126±22 0.126±30 0.99
Distolic blood pressue 
  (mmHg)
.074±13 00.73±13 0.91
Height (cm) .165±7.6 0.160±9.3 0.07
Weight (kg) .067±9.1 00.57±10.0 <0.01
Body mass index (kg/m
2) 24.7±2.3 022.2±2.4 <0.01
Waist circumference (cm)
Male 90.9±6.1 084.2±4.8 <0.01
Female .101±1.4 00.76±11.0 0.04
Waist/Hip circumference ratio
Male 0.94±0.06 00.89±0.04 0.02
Female 0.96±0.01 00.89±0.04 0.10
Fasting blood sugar (mg/dL) .158±82 0.137±72 0.42
Creatinine (mg/dL) 0.91±0.14 01.13±0.54 0.07
Lipid profile (mg/dL)
Total cholesterol  .171±40 0.160±36 0.35
Triglycerides .114±84 0.101±48 0.59
HDL-C .039±9 00.41±8 0.47
LDL-C .108±32 00.97±32 0.30
Biomarkers
PTX3 (ng/mL) 3.00±2.61 01.33±0.81 <0.01
hs-CRP (mg/dL) 1.38±1.47 01.33±1.51 0.91
Pro-BNP (pg/mL)  .324±356 .1330±2972 0.26
CK-MB (ng/mL) 22.8±38.5  012.7±17.1 0.33
Troponin-T (ng/mL) 0.37±0.84 00.28±0.55 0.69
FAT computed tomography
Total fat area (cm
2) .249±46 0.135±38.3  <0.01
Visceral fat area (cm
2) .136±21 00.63±17 <0.01
Subcutaneous fat area (cm
2) .115±36 00.72±26 <0.01
Visceral/Total area ratio 0.55±0.08 00.47±0.10 0.01
PTX3: pentraxin 3, SD: standard deviation, HDL-C: high density li-
poprotein-cholesterol, LDL-C: low density lipoprotein-cholesterol, 
hs-CRP: high sensitivity C-reactive protein, BNP: B type natriuretic 
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of serum PTX3 concentration, and in particular, on its role in 
the prognosis of acute myocardial infarction and chronic heart 
failure.
10)11) Recently, a correlation between serum PTX3 con-
centration and metabolic syndrome was investigated, and was 
shown to be related to arteriosclerosis or dyslipidemia.
15) 
In our study, the PTX3 concentration and metabolic syn-
drome were not correlated, likely because of the small num-
ber of patients included and that they had had a myocardial 
infarction, which alone caused the elevation of the PTX3 level. 
Peri et al.
10) have reported the role of PTX3 as an early marker 
of ischemic damage such as that in acute myocardial infarction, 
and showed that in these patients, the PTX3 level usually peaks 
7.5 hours after admission to the intensive care unit (ICU), while 
the CRP level is elevated 24 hours after admission to the ICU. 
Our study revealed that within 2 hours after arrival to the emer-
gency room, the serum PTX3 concentration was elevated to 
2.33 ng/mL (normal value: <0.99 ng/mL). Latini et al.
16) re-
ported that in acute myocardial patients, serum PTX3 concen-
trations are superior to levels of CRP or other biochemical mar-
kers as a long-term prognosis marker. 
CRP and serum PTX3 belong to the same PTX superfami-
ly; nonetheless, CRP is a short PTX synthesized in the liver 
primarily in response to IL-6 stimulation, and serum PTX3 is 
a long PTX synthesized in response to stimulation by IL-1 and 
TNF-α, and it has been known to be specifically and abun-
dantly present in cardiac muscle.
7-9) It has been shown that, 
unlike CRP, serum PTX3 is rapidly induced by several inflam-
matory cytokines and primarily secreted from vascular endo-
thelial cells.
17) PTX3 secreted from cardiac vascular endothe-
lial cells in response to several immunological signals
18) is ele-
vated not only in coronary artery diseases, but also in heart 
failure and has been reported to correlate with prognosis in 
heart failure.
11)
Recent studies have reported that adipocytes induce PTX3 
synthesis by secreting various inflammatory cytokines
19) Al-
berti et al.
13) have reported that serum PTX3 concentrations 
were higher in patients with visceral obesity than those with 
subcutaneous obesity. In our study, in acute myocardial in-
farction patients, subcutaneous fat and visceral fat were mea-
sured quantitatively by FAT-CT, and it was observed that in-
creases in PTX3 concentration were significantly associated 
with increases in visceral fat and abdominal fat areas. Never-
theless, there was no correlation between CRP or serum lipid 
levels and obesity; a statistical association with PTX3 concen-
tration was not seen either, which might be explained by the 
fact that acute myocardial infarctions were associated with ele-
vated levels of CRP and serum lipid values. Similarly, PTX3 le-
vels did not correlate with CRP levels and it has been shown 
that in acute myocardial infarction, their temporal and site dis-
tribution are different.
10) 
In acute myocardial patients, metabolic syndrome has been 
known to be a major risk factor for major cardiac events be-
cause the latter is associated with systemic inflammatory fac-
tors.
20)21) In addition, Yusuf et al.
22) have reported a close rela-
tionship between myocardial infarction and obesity; among 
obesity markers, the waist-hip circumference ratio was more im-
portant than BMI, which in particular emphasized the impor-
tance of visceral fat. In our study, similarly, 60% of patients had 
abdominal obesity; however, in cases with BMI ≥25 kg/m
2, it 
was low, namely 25%, likely because even in patients with nor-
mal BMI, abdominal obesity was shown in many cases (Fig. 3). 
Kip et al.
23) have reported that obesity itself is meaningful as 
A   B   C  
BMI: 23.0, WC: 83 cm, VFA: 81.5 cm2 BMI: 24.1, WC: 93 cm, VFA: 110.0 cm2 BMI: 28.5, WC: 102 cm, VFA: 127.4 cm2
Fig. 3. Images demonstrate our method for determining abdominal fat distribution on a CT scan obtained at the umbilicus. The white areas 
demonstrated on upper images were regarded as visceral fat tissue, and the white areas on lower images were regarded as total fat tissue 
(visceral fat and subcutaneous fat). (A) is the CT scan in patient with normal BMI and normal VFA, (B) in patient with normal BMI and central 
obesity, and (C) in patient with increased BMI and central obesity. BMI: body mass index, WC: waist circumference, VFA: visceral fat area.Byung-Ju Shim, et al.   313
a part of metabolic syndrome rather than as an independent 
risk factor for cardiovascular diseases. Therefore, abdominal 
obesity should be further emphasized as a risk factor for car-
diovascular diseases, together with obesity. 
The limitations of our study are that first, it was conducted 
on a small number of patients, and thus a correlation between 
serum PTX3 and metabolic syndrome could not be shown 
clearly. Second, it was conducted on myocardial infarction 
patients in a regional community hospital and thus it is dif-
ficult to generalize sociodemographic factors. Third, it was 
conducted on acute myocardial patients and thus the effects 
of medications such as statins could not be distinguished, 
and the precise relationship between serum lipid levels which 
is usually elevated in obese patients or CRP and abdominal 
obesity associated with myocardial infarction could not be 
assessed.
In addition, long-term follow-up is ongoing to ascertain 
whether high serum PTX3 concentration is associated with 
abdominal obesity and thus correlates with long-term clini-
cal cardiovascular complications. 
Our study documents that in acute myocardial infarction 
patients, the elavation of serum PTX3 concentration is not 
only due to cardiovascular disease, but also to abdominal 
visceral obesity as measured by FAT-CT. Therefore, the ele-
vation of serum PTX3 concentration could be used not only 
in the diagnosis and prognosis of cardiovascular diseases, 
but also as a marker predicting abdominal visceral obesity 
in acute myocardial infarction patients. 
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